Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that their parent(s)/guardian(s) can and will comply with the requirements of the protocol should be enrolled in the study.~* Written informed consent obtained from the parent(s) or guardian(s) of the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* A male or female having completed the primary study 109670 and who was primed with the investigational or Meningitec™ vaccines.~Exclusion Criteria:~Exclusion criteria for persistence study entry (i.e. Month 24, 36 or 48):~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the subject's first visit.~* History of meningococcal disease.~* Administration of a meningococcal polysaccharide or a meningococcal polysaccharide conjugate vaccine outside of study 109670.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history.~* Administration of immunoglobulins and/or blood products within the three months preceding the subjects first visit.~* Concurrently participating in another clinical study, within 30 days of study entry, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).~* Bleeding disorders, such as thrombocytopenia, or subjects on anti-coagulant therapy.~Additional exclusion criteria for booster vaccination (to be checked at Month 48):~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the booster vaccination.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* Hypersensitivity to any vaccine containing diphtheria toxoid or non-toxic diphtheria toxin protein and/or tetanus toxoid.~* History of hypersensitivity after previous administration of Meningitec or the investigational vaccines in study 109670.~* Hypersensitivity to latex.~* Planned administration/ administration of a vaccine not foreseen by the protocol within one month before and 30 days after the booster dose.~* Previous vaccination with any component of the vaccines within the last month.~* History of any neurological disorder or seizures (one episode of febrile convulsion does not constitute an exclusion criteria).~* Major congenital defects or serious chronic illness.~* Acute disease at the time of vaccination.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 23 Months
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Subjects who received GSK vaccine 134612 in the primary vaccination study 109069 and will be boosted 4 years after primary vaccination with the same meningococcal vaccine as given in the primary study.
- Group B (Type: ACTIVE_COMPARATOR): Subjects who received Meningitec™ vaccine in the primary vaccination study 109069 and will be boosted 4 years after primary vaccination with the same meningococcal vaccine as given in the primary study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete